One-Shot gene therapy aims to cure devastating blood disorder
NCT ID NCT07436767
Summary
This early-stage study is testing a one-time gene therapy injection called KL003 for people with severe sickle cell disease. The treatment involves collecting a patient's own blood stem cells, modifying them in a lab to produce healthy hemoglobin, and then returning them to the patient. The main goals are to see if the modified cells successfully engraft and produce healthy red blood cells, and to monitor for any safety issues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.